2021
Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study
Byrne M, Kurian T, Patel D, Tamari R, Hong S, Abdelhakim H, Klein V, Rojas P, Madhavan R, Kent A, Logan A, Lee C, Husnain M, Manning B, Tschernia N, Dias A, Margalski D, Goldenson B, Byrne N, Chen H, Petrova-Drus K, Sengsayadeth S, Goodman A, Howard D, Wood W, Gill S, Jimenez A, Gutman J, Gowda L, Metheny L, Bhatnagar B, Hamilton B, Mishra A, Savona M. Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study. Blood 2021, 138: 2922. DOI: 10.1182/blood-2021-154151.Peer-Reviewed Original ResearchNon-relapse mortalityMDS/AMLChronic GVHDPost-HCT mortalityPost-HCT relapseOverall survivalRelapse/progressionShorter overall survivalBM chimerismComplex karyotypeImproved OSMyeloablative conditioningHigher KPSMultivariate analysisSecondary MDS/AMLAdvisory CommitteeLarge multi-institutional cohortMDS/AML patientsMulti-center collaborative studyLow NRM ratePost-HCT outcomesAllogeneic HCT recipientsSpeakers bureauYear overall survivalInferior overall survival
2020
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant